“To show the drug was well tolerated was a very important step. In coming days or weeks we will put some further data out, which hopefully will be the biomarker data,” he said.
Synairgen says its drug well tolerated in phase II trial
Quick facts: Synairgen PLC
Price: 171 GBX
Market Cap: £341.85 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE